Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase II clinical trial for patients with primary liver cancer, demonstrated promising Phase I efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex Biotherapeutics is headquartered in San Francisco and has manufacturing, research and development activities based at the OHRI in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .
About the Ottawa Regional Cancer Foundation
The Ottawa Regional Cancer Foundation is dedicated to increasing cancer survivorship in Eastern Ontario and works to fill the gaps in services. The Cancer Foundation aims to reduce wait times, increase access to the latest therapies, provide care closer to home and improve quality of life for cancer patients and their families. For more information, please visit www.ottawacancer.ca
About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute (OHRI) is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with t
|SOURCE Jennerex, Inc.|
Copyright©2009 PR Newswire.
All rights reserved